An Economic Evaluation of Direct Oral Penicillin Challenge for De‐Labelling Low Risk Patients With a Penicillin Allergy Label
The penicillin allergy de-labelling pathway cost was ≥ 4-fold that of the DPC alone. Costs were up to 3 times higher in an acute compared to an elective setting. No short-term cost savings were identified from proactive or opportunistic penicillin allergy de-labelling in this study.
Authors
- B Jackson
- Caroline Thomas (ORCID: https://orcid.org/0000-0002-9906-691X)
- Richard K. Bestwick (ORCID: https://orcid.org/0009-0006-3844-6587)
- Rubén Mújica-Mota (ORCID: https://orcid.org/0000-0002-7430-2744)
- Louise Savic (ORCID: https://orcid.org/0000-0003-2681-2288)
- Kornelija Kildonaviciute (ORCID: https://orcid.org/0009-0008-2929-7000)
- Siraj Misbah (ORCID: https://orcid.org/0000-0003-1525-8795)
- Mamidipudi Thirumala Krishna (ORCID: https://orcid.org/0000-0003-2109-5777)
- Ricky H. Bhogal (ORCID: https://orcid.org/0000-0002-5053-7979)
- Bee Yean Ng (ORCID: https://orcid.org/0009-0008-9955-1561)
- C. Moriarty
Institutions
- University of Leeds (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- St James's University Hospital (GB)
- Oxford University Hospitals NHS Trust (GB)
- University of Birmingham (GB)
Publication Details
- Journal
- Clinical & Experimental Allergy
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1111/cea.14633
- Citations
- 2
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- National Institute for Health and Care Research